Overview

NIRS Ticagrelor Evaluation

Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The Impact of Ticagrelor on Coronary Atherosclerotic Lipid Pool and Inflammation Assessed by Near-Infrared Spectroscopy study will evaluate whether ticagrelor leads to a 20% reduction in the LCBI with NIRS/IVUS suggesting coronary plaque stabilization and reduced inflammation in patients already on long-term statin therapy undergoing non-urgent PCI. It is hypothesized that the treatment with ticagrelor following PCI will lead to a significant 20% reduction in the lipid pool as measured by NIRS/IVUS at follow-up when compared with baseline imaging, suggesting a reduction in inflammation and stabilization of the lipid core in atherosclerotic lesions not treated during the index procedure.
Phase:
Phase 4
Details
Lead Sponsor:
Medstar Health Research Institute
Collaborator:
AstraZeneca
Treatments:
Ticagrelor